Scandinavian Biopharma is expanding by hiring a PhD in cell- and molecular biology.
Teresa Holmlund has joined the company. She has a PhD in cell and molecular biology and ten years of academic research experience studying molecular mechanisms in mitochondrial disease, cancer and severe congenital neutropenia.
“It feels great to be a part of Scandinavian Biopharma. It’s really motivating to work with the development of a new vaccine that can contribute to improved public health”, says Holmlund.
Tony Hoos to replace Anders Ullman as Head of R&D and Medical Affairs and Chief Medical Officer from 1 April 2023. Anton (Tony) Hoos, M.D., Ph.D., MBA will become Head of R&D and Medical Affairs and Chief Medical Officer and replace Anders Ullman, M.D., Ph.D. who will retire. Tony Hoos…
Bruno Lucidi has been appointed permanent CEO of Karolinska Development. Bruno Lucidi has previously been founding CEO of Idenix and Chairman of Pharmasset. He has also held senior positions within Bristol-Myers Squibb, Johnson & Johnson and at GlaxoSmithKline. Since September 8, 2014, Bruno Lucidi is CEO of the Karolinska Development’s wholly owned…
The company has announced the relocation into new corporate headquarters located at Sydmarken 11 in Søborg, and the appointment of a new Chief Financial Officer. The move will accommodate Zealand’s continued workforce growth, which has been steadily increasing to support the number of clinical development programs as well as the…
Paul Hargreaves has been appointed Chief Development Officer (CDO), starting September 13. He will join the management team and have a key role in the clinical development of the company’s project portfolio. The appointment of Hargreaves as CDO marks an important step for Spago Nanomedical as the company continues to…
